Investors in the Magnificent Seven stocks, take note. As Arnott wrote in an email: "Whoever coined the expression 'Magnificent Seven' for these companies presumably didn't see the movie, where four of ...
Investors in the Magnificent Seven stocks, take note. As Arnott wrote in an email: "Whoever coined the expression 'Magnificent Seven' for these companies presumably didn't see the movie, where four of ...
That reminds us of the use of holding a more value-minded portfolio alongside such a fund, and in Europe the most obvious pick here tends to be Lightman European. The portfolio made 11 per cent in ...
Citigroup Inc. and UBS Group AG are organizing about €2 billion ($2.1 billion) of funding to back Bain Capital’s acquisition of German facility-management company Apleona Group GmbH — a rare deal amid ...
EU exports to the US reached $605.8 billion in 2024, according to the US Census Bureau. Pharmaceutical companies are particularly vulnerable, according to BI strategists Laurent Douillet and Kaidi ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) yesterday and set a price target of ...
MS without Barriers is a campaign led by Lina Nielsen in partnership with Sanofi "I remember so clearly that the image in the textbook was an older man in a wheelchair, and I thought 'that can't be me ...
Use your voice to deepen the dialogue and engage with stories of courage, endurance, community, triumph, and the pursuit of truth in SA. Contact the public editor with feedback for our journalists, ...
L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...
Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...